[BIO] Bio-Rad Laboratories, Inc.


Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 183.48 Change: 0.83 (0.45%)
Ext. hours: Change: 0 (0%)

chart BIO

Refresh chart

Strongest Trends Summary For BIO

BIO is in the long-term up 161% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test sy

Fundamental Ratios
Shares Outstanding EPS2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -11.92% Sales Growth - Q/Q-20.96% P/E84.52
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.01% ROE4.55% ROI3.44%
Current Ratio4.08 Quick Ratio2.93 Long Term Debt/Equity0.34 Debt Ratio0.19
Gross Margin54.87% Operating Margin7.66% Net Profit Margin4.68% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-330 K Cash From Investing Activities-27.99 M Cash From Operating Activities29.45 M Gross Profit270.11 M
Net Profit17.82 M Operating Profit34.35 M Total Assets3.33 B Total Current Assets1.7 B
Total Current Liabilities416.88 M Total Debt435.93 M Total Liabilities1.13 B Total Revenue472.82 M
Technical Data
High 52 week317.41 Low 52 week233.97 Last close296.72 Last change-0.85%
RSI48.26 Average true range9.52 Beta0.73 Volume71.23 K
Simple moving average 20 days-0.93% Simple moving average 50 days-2.38% Simple moving average 200 days5.89%
Performance Data
Performance Week-4.62% Performance Month1.68% Performance Quart9.76% Performance Half2.09%
Performance Year10.07% Performance Year-to-date-3.49% Volatility daily1.85% Volatility weekly4.13%
Volatility monthly8.46% Volatility yearly29.32% Relative Volume236.57% Average Volume249.47 K
New High0.51% New Low


2020-06-01 09:07:59 | Do Hedge Funds Love Bio-Rad Laboratories, Inc. BIO?

2020-05-15 15:06:07 | Bio-Rad Laboratories, Inc. -- Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.

2020-05-12 11:51:00 | Jefferies Picks 20 Global Health-Care Winners for a Post-Pandemic World

2020-05-07 18:06:09 | Bio-Rad Laboratories Inc BIO BIO.B Q1 2020 Earnings Call Transcript

2020-05-07 10:11:02 | Bio-Rad BIO Beats Q1 Earnings Estimates, Withdraws View

2020-05-06 20:25:12 | Bio-Rad Laboratories BIO Q1 Earnings and Revenues Surpass Estimates

2020-05-06 16:15:00 | Bio-Rad Reports First-Quarter 2020 Financial Results

2020-05-05 08:00:20 | The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

2020-05-04 19:27:00 | Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit

2020-05-04 11:12:40 | Were Hedge Funds Right About Bio-Rad Laboratories, Inc. BIO?

2020-05-03 15:37:03 | A Potentially Undervalued Trio to Consider

2020-04-30 16:51:00 | Bio-Rad’s SARS-CoV-2 COVID-19 Serology Test Granted FDA Emergency Use Authorization, the First Total Antibody Test to Receive EUA from the FDA

2020-04-30 09:00:00 | Yahoo Finance Presents: Joe Lonsdale

2020-04-29 12:34:04 | Earnings Preview: Bio-Rad Laboratories BIO Q1 Earnings Expected to Decline

2020-04-27 08:00:16 | Top Investors' Favorite Stocks Rally Amid Coronavirus Crash

2020-04-27 08:00:16 | Top Investors' Favorite Stocks Rally Amid Coronavirus Crash

2020-04-27 06:16:07 | A Rising Share Price Has Us Looking Closely At Bio-Rad Laboratories, Inc.'s NYSE:BIO P/E Ratio

2020-04-23 18:44:00 | Bio Rad Labs At Top End Of Buy Range With Earnings Due

2020-04-22 16:25:00 | Bio-Rad to Report First-Quarter 2020 Financial Results Wednesday, May 6, 2020

2020-04-21 10:35:30 | Bio-Rad Laboratories Rolls Out Shipping of Coronavirus Antibody Test

2020-04-21 08:30:00 | Bio-Rad Begins Shipping SARS-COV-2 COVID-19 Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity

2020-04-09 09:35:01 | Bio-Rad Rides on International Expansion Amid Cost Concerns

2020-04-09 09:23:01 | Bio-Rad Launches Serology Test to Detect Coronavirus Antibody

2020-04-09 08:30:00 | Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider

2020-04-08 10:34:00 | Bio-Rad Coronavirus Blood Test 'Could be Big,' Jefferies Says

2020-04-08 06:57:05 | Do You Like Bio-Rad Laboratories, Inc. NYSE:BIO At This P/E Ratio?

2020-04-07 08:30:00 | Bio-Rad Announces the Launch of a Serology Assay to Detect Coronavirus COVID-19 Antibodies

2020-04-06 13:55:29 | 5 Peter Lynch Stocks With a Margin of Safety

2020-04-02 09:42:07 | East Bay biotech hit by ransomware attack just 3 months after competitor hacked

2020-03-31 08:00:52 | Top Fund Manager Says These Stocks Should Soar In The Next Market Rally

2020-03-23 18:16:20 | 3 Medical Companies With the Strength to Weather Coronavirus Fears

2020-03-23 11:16:03 | Bio-Rad, Biodesix Partner to Get EUA for Coronavirus Test

2020-03-20 10:43:02 | Bio-Rad's ddPCR System Detects Coronavirus More Accurately

2020-03-20 07:00:00 | Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization EUA COVID-19 ddPCR™ Test to the U.S.

2020-03-19 17:30:00 | New Studies Find Bio-Rad’s QX200 Droplet Digital PCR System Can Detect COVID-19 With Greater Sensitivity and Precision Than Other Existing Molecular Tests

2020-03-19 07:37:15 | The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

2020-03-18 19:24:00 | Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing

2020-03-17 11:27:41 | Hedge Funds Have Never Been More Bullish On Bio-Rad Laboratories, Inc. BIO

2020-03-14 11:30:03 | Why Is Bio-Rad BIO Down 8.3% Since Last Earnings Report?

2020-03-13 09:45:01 | Bio-Rad Launches SARS CoV-2 Standard for Coronavirus Testing

2020-03-12 19:30:00 | Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus COVID-19 Testing

2020-03-09 13:30:10 | 6 Cheap Health Care Stocks

2020-03-09 08:34:48 | With EPS Growth And More, Bio-Rad Laboratories NYSE:BIO Is Interesting

2020-02-25 16:15:00 | Bio-Rad to Present at Barclays Global Healthcare Conference 2020 on March 10

2020-02-24 17:47:34 | As coronavirus fears hit markets, why are these Bay Area stocks rising?

2020-02-14 10:35:36 | Cyberattack costs East Bay biotech company $20 million

2020-02-14 08:53:01 | Bio-Rad BIO Q4 Earnings & Revenues Fall Short of Estimates

2020-02-14 01:58:53 | Edited Transcript of BIO earnings conference call or presentation 13-Feb-20 10:00pm GMT

2020-02-13 18:45:11 | Bio-Rad Laboratories BIO Misses Q4 Earnings and Revenue Estimates

2020-02-13 18:23:00 | CORRECTING and REPLACING Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results